CR20190002A - Combinaciones farmacéuticas - Google Patents

Combinaciones farmacéuticas

Info

Publication number
CR20190002A
CR20190002A CR20190002A CR20190002A CR20190002A CR 20190002 A CR20190002 A CR 20190002A CR 20190002 A CR20190002 A CR 20190002A CR 20190002 A CR20190002 A CR 20190002A CR 20190002 A CR20190002 A CR 20190002A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutically acceptable
del
pharmaceutical combinations
farmacéuticas
inhibidor
Prior art date
Application number
CR20190002A
Other languages
English (en)
Inventor
Giordano Caponigro
Zhu Alexander Cao
Original Assignee
Zhu Alexander Cao
Giordano Caponigro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhu Alexander Cao, Giordano Caponigro filed Critical Zhu Alexander Cao
Publication of CR20190002A publication Critical patent/CR20190002A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
CR20190002A 2016-06-03 2017-06-02 Combinaciones farmacéuticas CR20190002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03
PCT/US2017/035653 WO2017210538A1 (en) 2016-06-03 2017-06-02 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
CR20190002A true CR20190002A (es) 2019-06-10

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190002A CR20190002A (es) 2016-06-03 2017-06-02 Combinaciones farmacéuticas

Country Status (26)

Country Link
US (3) US10485788B2 (es)
EP (1) EP3463345B1 (es)
JP (2) JP6805336B2 (es)
KR (1) KR102439911B1 (es)
CN (1) CN109890386B (es)
AU (1) AU2017275650B2 (es)
BR (1) BR112018074941A2 (es)
CA (1) CA3026361A1 (es)
CL (1) CL2018003421A1 (es)
CO (1) CO2019000010A2 (es)
CR (1) CR20190002A (es)
DK (1) DK3463345T3 (es)
FI (1) FI3463345T3 (es)
HU (1) HUE060653T2 (es)
IL (1) IL263431A (es)
MA (1) MA45187A (es)
MX (1) MX2018014973A (es)
PH (1) PH12018502549A1 (es)
PL (1) PL3463345T3 (es)
PT (1) PT3463345T (es)
RU (1) RU2759669C2 (es)
SG (1) SG11201810793XA (es)
SI (1) SI3463345T1 (es)
UA (1) UA125436C2 (es)
WO (1) WO2017210538A1 (es)
ZA (1) ZA201900019B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190002A (es) 2016-06-03 2019-06-10 Zhu Alexander Cao Combinaciones farmacéuticas
BR112019005046A2 (pt) * 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
JP2022550978A (ja) * 2019-10-11 2022-12-06 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 薬剤用量決定デバイスおよび方法
US20230060581A1 (en) * 2020-02-10 2023-03-02 Cedars-Sinai Medical Center Method of treating pancreatic cancer
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PT2275102E (pt) 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
SI2324008T1 (sl) 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarilpirazoli kot protein-kinazni inhibitorji
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer
CN108542906A (zh) * 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
CN103945831A (zh) 2011-11-23 2014-07-23 诺华股份有限公司 医药制剂
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
LT2882440T (lt) * 2012-08-07 2019-04-25 Novartis Ag Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį
HRP20240033T1 (hr) 2012-10-19 2024-03-29 Array Biopharma, Inc. Formulacija koja sadrži inhibitor mek
JP2016503399A (ja) * 2012-10-25 2016-02-04 ノバルティス アーゲー 組合せ
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
EP3023407A4 (en) 2013-07-18 2017-03-15 Daicel Corporation Method for producing oxide
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
AU2014362995A1 (en) * 2013-12-12 2016-05-26 Novartis Ag Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
EP3279201B1 (en) * 2015-04-01 2019-10-23 Crystal Pharmatech Co., Ltd. Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
WO2017019279A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
CR20190002A (es) 2016-06-03 2019-06-10 Zhu Alexander Cao Combinaciones farmacéuticas

Also Published As

Publication number Publication date
PT3463345T (pt) 2023-01-06
UA125436C2 (uk) 2022-03-09
CN109890386A (zh) 2019-06-14
KR20190119507A (ko) 2019-10-22
MA45187A (fr) 2019-04-10
CL2018003421A1 (es) 2019-07-19
SG11201810793XA (en) 2018-12-28
US11376239B2 (en) 2022-07-05
HUE060653T2 (hu) 2023-04-28
US20230044943A1 (en) 2023-02-09
JP6805336B2 (ja) 2020-12-23
EP3463345A4 (en) 2020-02-26
JP2021054832A (ja) 2021-04-08
RU2018146812A3 (es) 2020-10-09
DK3463345T3 (da) 2023-01-09
AU2017275650B2 (en) 2023-06-01
CN109890386B (zh) 2022-05-24
US10485788B2 (en) 2019-11-26
PL3463345T3 (pl) 2023-02-06
EP3463345B1 (en) 2022-11-02
US20190105303A1 (en) 2019-04-11
US20200230108A1 (en) 2020-07-23
AU2017275650A1 (en) 2019-01-17
MX2018014973A (es) 2019-12-18
ZA201900019B (en) 2023-04-26
PH12018502549A1 (en) 2019-04-08
IL263431A (en) 2019-01-31
KR102439911B1 (ko) 2022-09-05
BR112018074941A2 (pt) 2019-03-12
EP3463345A1 (en) 2019-04-10
CA3026361A1 (en) 2017-12-07
RU2018146812A (ru) 2020-07-09
WO2017210538A1 (en) 2017-12-07
FI3463345T3 (fi) 2023-01-31
JP2019525948A (ja) 2019-09-12
SI3463345T1 (sl) 2023-02-28
RU2759669C2 (ru) 2021-11-16
CO2019000010A2 (es) 2019-05-21

Similar Documents

Publication Publication Date Title
CR20190002A (es) Combinaciones farmacéuticas
CL2016003293A1 (es) Inhibidores de mnk y método relacionado al mismo
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CR20190376A (es) Formulaciones de anticuerpos de her2 subcutáneas
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
CL2017000050A1 (es) Terapia de combinación para el cáncer
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
EP3626239A4 (en) USE OF AN EZH2 INHIBITOR COMBINED WITH A BTK INHIBITOR IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF TUMOR
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
CL2020001131A1 (es) Administración oral de análogos del péptido glp-1.
AR113450A1 (es) Vectores adenovirales competentes en la replicación
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2017016346A (es) Metodos de tratamiento con taselisib.
AR100289A1 (es) Formas de un inhibidor de pi3k
EP3153178A4 (en) Method for treating cancer patients using folr1 targeted drug and antifolate, and drug
MX2021007853A (es) Compuestos de tienopiridinona.